
A large, Harvard-led study claims that taking statin cholesterol-lowering drugs reduces the risk of heart attack and stroke among people with “silent heart disease” and normal cholesterol levels.
The study, named JUPITER, involved over 17,800 people who had high C-reactive protein levels, which previous studies have shown are an indicator of inflammation and heart disease risk, even among those otherwise considered healthy.
The study divided the subjects into two groups, with half receiving rosuvastatin (Crestor) and the rest receiving a placebo. The results showed a nearly 50 percent reduction in the risk of heart attack, stroke, and heart-related death among the statin group.
Based on the seemingly promising results, an independent data and safety monitoring board voted to end the study early, after less than two years.
Not everyone is jumping for joy over the study’s results, however. Many physicians are skeptical of statins’ perceived benefits, particulalry because the study was funded by the drug company Astra-Zeneca, the maker of the statin drug used in the trial.